ACE Inhibitor or ARB as the Third Antihypertensive Agent in Adults with Diabetes

1. Rationale for Adding an ACE Inhibitor or ARB

• The Canadian Cardiovascular Society (CCS) recommends that, for adults with diabetes and hypertension, ACE inhibitors or ARBs should be the preferred third‑line agents because they provide cardiovascular protection beyond blood‑pressure reduction (Grade A)【1】【4】.
• ACE inhibitors and ARBs confer renal protection and markedly slow the progression of albuminuria in diabetic patients (Grade A)【1】【4】【5】.
• Use of these agents reduces microvascular complications such as diabetic retinopathy (Grade A)【4】【5】.
• Adding an ACE inhibitor or ARB specifically addresses the renin‑angiotensin system, which remains unmodulated when a patient is already on a β‑blocker and a vasodilator【1】【2】.

2. Selecting Between ACE Inhibitor and ARB

2.1 When to Choose an ACE Inhibitor

• Preferred if the patient has no prior ACE‑inhibitor‑induced cough, is non‑Black, and cost is a concern (ACE inhibitors are generally less expensive)【2】【3】【1】.
• CCS grades the evidence for ACE inhibitors in non‑Black diabetic patients as Grade A【2】【3】.

Typical dosing (CCS‑endorsed):

2.2 When to Choose an ARB

• Preferred if the patient has a history of ACE‑inhibitor‑induced cough, is Black, or has left‑ventricular hypertrophy【2】【3】【1】.
• CCS assigns Grade A evidence to ARBs for Black patients with LVH【1】.

Typical dosing (CCS‑endorsed):

3. Monitoring After Initiation

• Laboratory checks: Serum creatinine and potassium should be measured 1–2 weeks after starting an ACE inhibitor or ARB【1】【2】.
• Acceptable creatinine rise: Up to 30 % above baseline is considered safe【1】.
• Hyper‑kalaemia threshold: Hold the medication if potassium exceeds 5.5 mmol/L【2】.
• Blood‑pressure follow‑up: Check BP monthly until the target of <130/80 mmHg is reached【1】【4】.

4. Blood‑Pressure Target

• CCS sets the target BP at <130/80 mmHg for adults with diabetes (Grade A)【1】【4】【5】.

If the target is not achieved after adding an ACE inhibitor/ARB:

• Add a long‑acting dihydropyridine CCB (e.g., amlodipine 5–10 mg daily) as the fourth agent【2】【3】.
• This four‑drug regimen (β‑blocker + vasodilator + ACE/ARB + CCB) provides complementary mechanisms for BP control【2】【6】.

5. Contraindications & Safety Considerations

• Do not combine an ACE inhibitor with an ARB – CCS cites Grade A evidence of increased risk for hyperkalaemia, acute kidney injury, and hypotension without added cardiovascular benefit【2】【3】【7】.
• Avoid non‑dihydropyridine CCBs (diltiazem, verapamil) when a β‑blocker is present, due to the risk of severe bradycardia and heart block【2】【3】【7】.
• Monitor for hypotension because the patient is already on two antihypertensives (β‑blocker + vasodilator)【2】【3】.

6. Role of Albuminuria in Therapy Choice

• If the urine albumin‑to‑creatinine ratio (ACR) exceeds 2.0 mg/mmol (men) or 2.8 mg/mmol (women), an ACE inhibitor or ARB becomes mandatory first‑line therapy (Grade A)【1】.
• When albuminuria is present, the ACE inhibitor or ARB should be titrated to the maximum tolerated dose before introducing additional agents【1】【4】.